Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vyvanse lisdexamfetamine dimesylate regulatory update

FDA approved an sNDA from Shire for Vyvanse lisdexamfetamine dimesylate as maintenance treatment of ADHD

Read the full 159 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE